Teriflunomide for the treatment of multiple sclerosis

Jiwon Oh, Paul W. O'Connor

Research output: Contribution to journalArticlepeer-review


Several novel oral agents are emerging for use in multiple sclerosis (MS). Among these oral agents, teriflunomide is showing promise with respect to clinical efficacy and safety in relapsing MS patients. In this review, the authors clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing salient points on the use of teriflunomide in MS, with a discussion of teriflunomide's development, pharmacologic properties, preclinical and clinical trials, and safety and tolerability.

Original languageEnglish (US)
Pages (from-to)45-55
Number of pages11
JournalSeminars in neurology
Issue number1
StatePublished - 2013


  • clinical trials
  • multiple sclerosis
  • teriflunomide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Teriflunomide for the treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this